Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the research, development, and commercialization of innovative therapies that modulate cortisol activity. With over 25 years of experience and a portfolio that includes more than 1,000 proprietary molecules, the company focuses on unlocking the therapeutic potential of targeting the glucocorticoid receptor, which plays a central role in physiological and psychological processes regulated by cortisol, often referred to as the “stress hormone.” Corcept’s primary purpose is to address serious diseases that are impacted by abnormal cortisol function, spanning multiple sectors including endocrinology, oncology, metabolism, and neurology. Its marketed product, Korlym (mifepristone), is approved for controlling hyperglycemia in Cushing’s syndrome, and its pipeline features candidates for conditions such as nonalcoholic steatohepatitis, various cancers, and psychiatric disorders. Corcept Therapeutics is recognized for its scientific leadership in cortisol modulation and maintains a strong commitment to advancing novel solutions for unmet medical needs through extensive clinical research and collaboration within the global healthcare sector.